Antioxidants in prevention of cataracts in South India

Methodology and baseline data

David C. Gritz, Muthiah Srinivasan, Scott D. Smith, Usha Kim, Thomas M. Lietman, John H. Wilkins, Brinda Priyadharshini, Srinivasan Aravind, N. Venkatesh Prajna, Gilbert Smolin, Ravilla Duraisami Thulasiraj, Sivasubramaniam Selvaraj, John P. Whitcher

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Purpose: To describe the methodology and baseline data for the Antioxidants in Prevention of Cataracts (APC) study in South India. Methods: The APC study is a prospective, 5-year, randomized, triple-masked, placebo-controlled, field-based clinical trial to examine the effect of antioxidants (combination tablet of vitamins A, C, and E) on progression of cataract. The primary outcome variable is cataract progression (nuclear opalescence), evaluated with the slit-lamp biomicroscope by the Lens Opacification Classification System III method. Secondary outcome variables are progression in cortical and posterior subcapsular opacity and nuclear color, change in best corrected visual acuity, myopic shift, and treatment failure (progression to cataract surgery or best corrected vision worse than 20/400 in an eye). Inclusion criteria are age between 35 and 50 years and best-corrected visual acuity of 20/40 or better. Exclusion criteria are a diagnosis of diabetes mellitus or nonfasting blood glucose level >7.8 mmol/L, history or presence of various ocular conditions or treatment forms, or current use of vitamin supplements. Baseline ophthalmic, demographic, and potential cataract risk factor data (such as smoking, sunlight, or alcohol exposure) were compared between groups on an intent-to-treat basis. Results: Of 954 people screened, 798 were enrolled, a sample size which exceeded the required estimate. More than 80% of subjects had 20/20 or better vision in at least one eye, and baseline prevalence of significant cataract according to the LOCS III grading scale was high. The two treatment groups were comparable for all baseline measures except alcohol intake. Conclusion: The sample size and group baseline characteristics will provide sufficient power to detect a change in cataract progression within 5 years.

Original languageEnglish (US)
Pages (from-to)97-107
Number of pages11
JournalOphthalmic Epidemiology
Volume13
Issue number2
DOIs
StatePublished - Apr 2006
Externally publishedYes

Fingerprint

Cataract
India
Antioxidants
Sample Size
Visual Acuity
Alcohols
Sunlight
Treatment Failure
Vitamin A
Vitamin E
Vitamins
Lenses
Tablets
Ascorbic Acid
Blood Glucose
Diabetes Mellitus
Color
Smoking
History
Placebos

Keywords

  • Antioxidants
  • APC study
  • Ascorbic acid
  • Beta carotene
  • Cataract prevention
  • Developing countries
  • India
  • Preventive medicine
  • Randomized controlled trial
  • Vitamin E

ASJC Scopus subject areas

  • Ophthalmology
  • Epidemiology

Cite this

Gritz, D. C., Srinivasan, M., Smith, S. D., Kim, U., Lietman, T. M., Wilkins, J. H., ... Whitcher, J. P. (2006). Antioxidants in prevention of cataracts in South India: Methodology and baseline data. Ophthalmic Epidemiology, 13(2), 97-107. https://doi.org/10.1080/09286580500477366

Antioxidants in prevention of cataracts in South India : Methodology and baseline data. / Gritz, David C.; Srinivasan, Muthiah; Smith, Scott D.; Kim, Usha; Lietman, Thomas M.; Wilkins, John H.; Priyadharshini, Brinda; Aravind, Srinivasan; Prajna, N. Venkatesh; Smolin, Gilbert; Thulasiraj, Ravilla Duraisami; Selvaraj, Sivasubramaniam; Whitcher, John P.

In: Ophthalmic Epidemiology, Vol. 13, No. 2, 04.2006, p. 97-107.

Research output: Contribution to journalArticle

Gritz, DC, Srinivasan, M, Smith, SD, Kim, U, Lietman, TM, Wilkins, JH, Priyadharshini, B, Aravind, S, Prajna, NV, Smolin, G, Thulasiraj, RD, Selvaraj, S & Whitcher, JP 2006, 'Antioxidants in prevention of cataracts in South India: Methodology and baseline data', Ophthalmic Epidemiology, vol. 13, no. 2, pp. 97-107. https://doi.org/10.1080/09286580500477366
Gritz, David C. ; Srinivasan, Muthiah ; Smith, Scott D. ; Kim, Usha ; Lietman, Thomas M. ; Wilkins, John H. ; Priyadharshini, Brinda ; Aravind, Srinivasan ; Prajna, N. Venkatesh ; Smolin, Gilbert ; Thulasiraj, Ravilla Duraisami ; Selvaraj, Sivasubramaniam ; Whitcher, John P. / Antioxidants in prevention of cataracts in South India : Methodology and baseline data. In: Ophthalmic Epidemiology. 2006 ; Vol. 13, No. 2. pp. 97-107.
@article{4aa34dac93ac4167aeb578347b93d6f8,
title = "Antioxidants in prevention of cataracts in South India: Methodology and baseline data",
abstract = "Purpose: To describe the methodology and baseline data for the Antioxidants in Prevention of Cataracts (APC) study in South India. Methods: The APC study is a prospective, 5-year, randomized, triple-masked, placebo-controlled, field-based clinical trial to examine the effect of antioxidants (combination tablet of vitamins A, C, and E) on progression of cataract. The primary outcome variable is cataract progression (nuclear opalescence), evaluated with the slit-lamp biomicroscope by the Lens Opacification Classification System III method. Secondary outcome variables are progression in cortical and posterior subcapsular opacity and nuclear color, change in best corrected visual acuity, myopic shift, and treatment failure (progression to cataract surgery or best corrected vision worse than 20/400 in an eye). Inclusion criteria are age between 35 and 50 years and best-corrected visual acuity of 20/40 or better. Exclusion criteria are a diagnosis of diabetes mellitus or nonfasting blood glucose level >7.8 mmol/L, history or presence of various ocular conditions or treatment forms, or current use of vitamin supplements. Baseline ophthalmic, demographic, and potential cataract risk factor data (such as smoking, sunlight, or alcohol exposure) were compared between groups on an intent-to-treat basis. Results: Of 954 people screened, 798 were enrolled, a sample size which exceeded the required estimate. More than 80{\%} of subjects had 20/20 or better vision in at least one eye, and baseline prevalence of significant cataract according to the LOCS III grading scale was high. The two treatment groups were comparable for all baseline measures except alcohol intake. Conclusion: The sample size and group baseline characteristics will provide sufficient power to detect a change in cataract progression within 5 years.",
keywords = "Antioxidants, APC study, Ascorbic acid, Beta carotene, Cataract prevention, Developing countries, India, Preventive medicine, Randomized controlled trial, Vitamin E",
author = "Gritz, {David C.} and Muthiah Srinivasan and Smith, {Scott D.} and Usha Kim and Lietman, {Thomas M.} and Wilkins, {John H.} and Brinda Priyadharshini and Srinivasan Aravind and Prajna, {N. Venkatesh} and Gilbert Smolin and Thulasiraj, {Ravilla Duraisami} and Sivasubramaniam Selvaraj and Whitcher, {John P.}",
year = "2006",
month = "4",
doi = "10.1080/09286580500477366",
language = "English (US)",
volume = "13",
pages = "97--107",
journal = "Ophthalmic Epidemiology",
issn = "0928-6586",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Antioxidants in prevention of cataracts in South India

T2 - Methodology and baseline data

AU - Gritz, David C.

AU - Srinivasan, Muthiah

AU - Smith, Scott D.

AU - Kim, Usha

AU - Lietman, Thomas M.

AU - Wilkins, John H.

AU - Priyadharshini, Brinda

AU - Aravind, Srinivasan

AU - Prajna, N. Venkatesh

AU - Smolin, Gilbert

AU - Thulasiraj, Ravilla Duraisami

AU - Selvaraj, Sivasubramaniam

AU - Whitcher, John P.

PY - 2006/4

Y1 - 2006/4

N2 - Purpose: To describe the methodology and baseline data for the Antioxidants in Prevention of Cataracts (APC) study in South India. Methods: The APC study is a prospective, 5-year, randomized, triple-masked, placebo-controlled, field-based clinical trial to examine the effect of antioxidants (combination tablet of vitamins A, C, and E) on progression of cataract. The primary outcome variable is cataract progression (nuclear opalescence), evaluated with the slit-lamp biomicroscope by the Lens Opacification Classification System III method. Secondary outcome variables are progression in cortical and posterior subcapsular opacity and nuclear color, change in best corrected visual acuity, myopic shift, and treatment failure (progression to cataract surgery or best corrected vision worse than 20/400 in an eye). Inclusion criteria are age between 35 and 50 years and best-corrected visual acuity of 20/40 or better. Exclusion criteria are a diagnosis of diabetes mellitus or nonfasting blood glucose level >7.8 mmol/L, history or presence of various ocular conditions or treatment forms, or current use of vitamin supplements. Baseline ophthalmic, demographic, and potential cataract risk factor data (such as smoking, sunlight, or alcohol exposure) were compared between groups on an intent-to-treat basis. Results: Of 954 people screened, 798 were enrolled, a sample size which exceeded the required estimate. More than 80% of subjects had 20/20 or better vision in at least one eye, and baseline prevalence of significant cataract according to the LOCS III grading scale was high. The two treatment groups were comparable for all baseline measures except alcohol intake. Conclusion: The sample size and group baseline characteristics will provide sufficient power to detect a change in cataract progression within 5 years.

AB - Purpose: To describe the methodology and baseline data for the Antioxidants in Prevention of Cataracts (APC) study in South India. Methods: The APC study is a prospective, 5-year, randomized, triple-masked, placebo-controlled, field-based clinical trial to examine the effect of antioxidants (combination tablet of vitamins A, C, and E) on progression of cataract. The primary outcome variable is cataract progression (nuclear opalescence), evaluated with the slit-lamp biomicroscope by the Lens Opacification Classification System III method. Secondary outcome variables are progression in cortical and posterior subcapsular opacity and nuclear color, change in best corrected visual acuity, myopic shift, and treatment failure (progression to cataract surgery or best corrected vision worse than 20/400 in an eye). Inclusion criteria are age between 35 and 50 years and best-corrected visual acuity of 20/40 or better. Exclusion criteria are a diagnosis of diabetes mellitus or nonfasting blood glucose level >7.8 mmol/L, history or presence of various ocular conditions or treatment forms, or current use of vitamin supplements. Baseline ophthalmic, demographic, and potential cataract risk factor data (such as smoking, sunlight, or alcohol exposure) were compared between groups on an intent-to-treat basis. Results: Of 954 people screened, 798 were enrolled, a sample size which exceeded the required estimate. More than 80% of subjects had 20/20 or better vision in at least one eye, and baseline prevalence of significant cataract according to the LOCS III grading scale was high. The two treatment groups were comparable for all baseline measures except alcohol intake. Conclusion: The sample size and group baseline characteristics will provide sufficient power to detect a change in cataract progression within 5 years.

KW - Antioxidants

KW - APC study

KW - Ascorbic acid

KW - Beta carotene

KW - Cataract prevention

KW - Developing countries

KW - India

KW - Preventive medicine

KW - Randomized controlled trial

KW - Vitamin E

UR - http://www.scopus.com/inward/record.url?scp=33645644281&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645644281&partnerID=8YFLogxK

U2 - 10.1080/09286580500477366

DO - 10.1080/09286580500477366

M3 - Article

VL - 13

SP - 97

EP - 107

JO - Ophthalmic Epidemiology

JF - Ophthalmic Epidemiology

SN - 0928-6586

IS - 2

ER -